Cephalosporin Drugs Market, By Generation (First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, Fifth-Generation Cephalosporin), By Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others), By Route of Administration (Oral Drugs, Injection), By Type (Branded and Generic), and By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and the Rest of the World) – Market Size & Forecasting (2017-2028)

The global cephalosporin drugs market was valued at USD 11.6 billion in 2018 and is expected to grow at a CAGR of 5.2% during the forecast period. Cephalosporin may be a bactericidal, broad-spectrum, β-lactam antibiotic originally derived from the fungus Acremonium that's wont to treat bacterial infections like pneumonia, skin infections, streptococcal sore throat, staph infections, tonsillitis, bronchitis, otitis, gonorrhea, et al. It resembles penicillin and hence is employed as an alternative for patients who are allergic to penicillin. a rise in the incidence of the population affected by pneumonia, tonsillitis, bronchitis, and gonorrhea drives the market growth. In addition to this, increased R&D activities to develop highly effective and safe drugs, expanded use of combination therapies drive market growth and raise the incidence of pneumonia, tonsillitis, bronchitis, and gonorrhea. Consequently, these factors help to increase the global market share of cephalosporin.

Cephalosporin Drugs Market stats

Cephalosporin Drugs Market Statistics

The global cephalosporin drugs market is predicted to grow substantially thanks to increasing demand for anti-microbial in various indications, rising research and development activities, growing awareness among patients, and increasing prevalence of infectious diseases. Per annum, November 18 is widely known because of the European Antibiotic Awareness Day, which helps to extend awareness about antibiotic resistance and promotes the judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, thereby boosting the expansion of the cephalosporin drugs market. Additionally, low investment in R&D, stringent government policies, and generic saturation of those drugs fuel the expansion of the market. Moreover, increasing mergers and acquisitions, the use of combination therapies for treatment, and the development of safe and highly efficient cephalosporin drugs are other factors likely to contribute to the expansion of the market. However, weak pipeline molecules, development of drug resistance and resistance by governments on drug development are some challenges within the global cephalosporin drugs market.

Key Factors Impacting the Growth of Cephalosporin Drugs Market:

  • The research and development are expected to drive the growth of the demand in the market
  • Growth prospects in the developing nations in 2026

Cephalosporin Drugs Market Segments

Cephalosporin Drugs Market By Segmentation (2017-2028)

The cephalosporin drugs market segmentation is based on generations, applications, route of administration, type, and region.

Generation Outlook:

Based on generation, the cephalosporin drugs market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, fifth-generation cephalosporin. Moreover, in 2018, the third-generation cephalosporin is estimated to dominate the market in terms of value. The growth is mainly influenced due to the increase in use for the treatment of gram-negative bacillary meningitis and serious infections of enterobacteriaceae.

Application Outlook:

Based on the application, the global cephalosporin drugs market size is divided into respiratory tract infection, skin infection, ear infection, sexually transmitted infection and others. Moreover, in 2018, the respiratory tract infection is estimated to dominate the market in terms of value.

Regional Outlook:

Based on the region, the global cephalosporin drugs market has been segmented by North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, & Rest of the World. Increases in awareness for cerebrosporin drugs in patients, increasing demand for a highly developed health infrastructure and overwhelming populations with infectious conditions have dominated the world market for cephalosporin products in the Asia Pacific. In addition, the highest growth rate in the market due to the increased prevalence of infectious diseases has made North America the most attractive market.

This report analyzes both demand and supply factors that influence the market for Cephalosporin drugs and analyzes further the market dynamics of drivers, restraint, opportunities and future trends during the forecast year. The report also provides comprehensive Porter’s model analysis on the cephalosporin drugs market for all six regions namely; North America, Western Europe, Eastern Europe, Asia Pacific, Middle East and the Rest of the world.

Cephalosporin Drugs Market RegionCephalosporin Drugs Market By Regional Analysis (2017-2028)

Competitive Landscape

Innovative advancement in cephalosporin drugs helps to maintain patient and group health track record to improve patient engagement, data aggregation, and remote monitoring. Major companies are investing in research and development. Key market players are also adopting inorganic development strategies like as acquisition of local brands. Similarly, other models like joint venture and market enterprise strategies help prominent vendors to show their presence and increase their portfolio in the market for cephalosporin drugs. The key leading players in the market include Ranbaxy, Merck, Sandoz, Pfizer, Astellas, Roche, Bristol-Myers Squibb, Abbott, Lupin Pharmaceuticals, Teva Pharmaceuticals, and Glaxo SmithKline.

This report also includes the profiles of key cephalosporin drugs market companies along with their SWOT analysis and market strategies. In addition, these competitive landscapes provide a detailed description of each company including future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new generation launch, new generation developments, and other latest industrial developments.

Key Developments in Cephalosporin Drugs Market:

  • In April 2019, Autolus Therapeutics PLC was granted with an orphan drug designation, to autolus enriched T-cells, genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 for the treatment of Respiratory Tract Infection (ALL), by the US FDA
  • In April 2019, Cellectis received approval from the US FDA to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM).
  • In May 2018, Kite Pharma leased a new facility for cell therapy engineering in Europe in the Netherlands with the aim of strengthening its position on the global market for CAR T-cell therapy.

Cephalosporin Drugs Market

Cephalosporin Drugs Market Timeline (2017-2028)

What Does This Report Provide?

This report provides a detailed understanding of the global cephalosporin drugs market from qualitative and quantitative perspectives during the forecast period. The study also includes competitive metrics with potential market effects during the forecast period, and an in-depth overview of the market's leading companies.

Market Segmentation:

By Generation

  • First-Generation Cephalosporin
  • Second-Generation Cephalosporin
  • Third-Generation Cephalosporin
  • Fourth-Generation Cephalosporin
  • Fifth-Generation Cephalosporin

By Application

  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Sexually Transmitted Infection
  • Other

By Route of Administration

  • Oral Drugs
  • Injection

By Type

  • Branded
  • Generic

By Region:

  • North America
    • By Country (US, Canada, Mexico)
    • By Generation
    • By Application
    • By Route of Administration
    • By Type
  • Europe
    • By Country (Germany, UK, France, Italy, Spain, Rest of Europe)
    • By Generation
    • By Application
    • By Route of Administration
    • By Type
  • Asia Pacific
    • By Country (China, Japan, India, New Zealand, Australia, Rest of Asia Pacific)
    • By Generation
    • By Application
    • By Route of Administration
    • By Type
  • Middle East
    • By Country (UAE, Saudi Arabia, Rest of Middle East)
    • By Generation
    • By Application
    • By Route of Administration
    • By Type
  • Latin America
    • By Country (Argentina, Brazil, Rest of Latin America)
    • By Generation
    • By Application
    • By Route of Administration
    • By Type
  • Rest of the World
    • By Region (South Africa and Other)
    • By Generation
    • By Application
    • By Route of Administration
    • By Type

Reasons to Buy This Report:

  • Market size estimation of the cephalosporin drugs market on a regional and global basis
  • Unique research usage for market size estimation and forecast
  • Profiling of major companies operating in the market with key developments
  • Broad scope to cover all the possible segments helping every stakeholder in the cephalosporin drugs market

Customization:

We provide customization of the study to meet specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country

For more information, contact: sales@quincemarketinsights.com